Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on "Dr. Reddy's Laboratories
announces the launch of Neostigmine Methylsulfate Injection, USP in the U.S. Market."
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
Encl: New York Stock Exchange (Stock Code: RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | Saunak SAVLA saunaks@drreddys.com (P h : +91-40-49002135) | Calvin Printer calvinprinter@drreddys.com (Ph: +91-40- 49002121) |
Reddy's Laboratories announces the launch of
Methylsulfate Injection, USP in the U.S. Market
Hyderabad, India and Princeton,
NJ, USA. September 12, 2018- Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE:
DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch
of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (Neostigmine Methylsulfate)
Injection approved by the U.S. Food and Drug Administration (USFDA).
The Bloxiverz brand and generic had U.S. sales of approximately
$111 million MAT for the most recent twelve months ending in July 2018 according to IMS Health*.
Dr. Reddy's Neostigmine Methylsulfate Injection, USP is
available in 5 mg/10 mL and 10 mg/10 mL multi-dose vials.
Please click here for full Prescribing Information.
Bloxiverz is a registered trademark of Avadel Legacy Pharmaceuticals
*IMS National Sales Perspective: Retail and Non-Retail MAT July
About Dr. Reddy's: Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics
and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical
services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,
diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets
include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context,
the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from
those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets,
credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events
(ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes
in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization
, including related integration issues.
The company assumes no obligation to update any information